AI Impact on Drug Discovery is Still in Early Stages
Dow Jones
Yesterday
1331 GMT - The healthcare and life-sciences sector is increasingly turning to AI, but the technology's impact on drug discovery remains in the second or third inning, analysts at Citi say in a research note. "AI's initial impact is likely to be on productivity, speed, and cost avoidance vs. an improvement in [research-and-development] success rates," Citi says. Still, AI is starting to seep into the clinical setting and reshaping biopharma, the analysts say. Big pharma companies increasingly view AI as a tool to enable identification of targets for new drugs, design new medicines and develop them, they add.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.